Avalon's Laboratory Services MSO Launches DNA Testing Kit For Predisposition To Opioid Addiction
Author: Benzinga Newsdesk | July 31, 2024 08:21am
Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC ("LSM") has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence. To purchase or find out more information, please visit www.dna4addiction.com. Avalon owns a 40% equity interest in LSM.
Posted In: ALBT